TERN
Terns Pharmaceuticals, Inc.$52.97+0.02 (+0.04%)Prev Close$52.95·MCap$4.76B·P/E—·Vol3.83M·Yield—
▲
Buys (12M)
3
$186.6K
▼
Sells (12M)
9
$7.59M
◆
Net Activity
Net Seller
$7.40M
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Terns Pharmaceuticals, Inc. (TERN) has been dominated by selling, with 3 insider purchases totaling $186.6K and 9 insider sales totaling $7.59M. The most recent insider transaction was by Burroughs Amy L. (director, officer: Chief Executive Officer), who sold $681.1K worth of shares on Mar 17, 2026. Terns Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $4.76B.
TERN Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | Burroughs Amy L. | director, officer: Chief Executive Officer | Sell | 14,583 | $46.71 | $681.1K | 291,746 |
| Feb 18, 2026 | Burroughs Amy L. | director, officer: Chief Executive Officer | Sell | 14,583 | $39.19 | $571.6K | 301,218 |
| Feb 17, 2026 | Burroughs Amy L. | Chief Executive Officer | Sell | 14,583 | $39.19 | $571.6K | 0 |
| Jan 16, 2026 | Burroughs Amy L. | director, officer: Chief Executive Officer | Sell | 68,749 | $37.07 | $2.55M | 296,497 |
| Jan 6, 2026 | Burroughs Amy L. | director, officer: Chief Executive Officer | Sell | 71,339 | $38.10 | $2.72M | 138,976-34% |
| Jan 6, 2026 | Kuriakose Emil | officer: Chief Medical Officer | Sell | 1,155 | $38.57 | $44.6K | 51,320 |
| Nov 5, 2025 | Quigley Jill M. | Sell | 24,520 | $18.00 | $441.4K | 0Exit | |
| Oct 2, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 944 | $7.85 | $7.4K | 51,520 |
| Jul 3, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 853 | $4.27 | $3.6K | 52,464 |
| Jun 30, 2025 | Gengos Andrew | Chief Financial Officer | Buy | 10,000 | $3.93 | $39.3K | 25,000+67% |
| Jun 25, 2025 | Burroughs Amy L. | Chief Executive Officer | Buy | 23,314 | $3.87 | $90.2K | 47,083+98% |
| Jun 16, 2025 | Gengos Andrew | Chief Financial Officer | Buy | 15,000 | $3.81 | $57.1K | 15,000 |
| Apr 2, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 952 | $2.49 | $2.4K | 53,317 |
| Feb 3, 2025 | Burroughs Amy L. | Chief Executive Officer | Buy | 510 | $5.11 | $2.6K | 19,609 |
| Feb 3, 2025 | Jung Melita Sun | Chief Business Officer | Buy | 2,250 | $5.11 | $11.5K | 2,250 |
| Jan 6, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 4,481 | $5.71 | $25.6K | 54,269 |
| Jan 6, 2025 | Quigley Jill M. | Sell | 15,000 | $5.76 | $86.5K | 8,760-63% | |
| Jan 6, 2025 | Vignola Mark J. | Chief Financial Officer | Sell | 17,188 | $5.76 | $99.0K | 83,811 |
| Dec 9, 2024 | Burroughs Amy L. | Chief Executive Officer | Buy | 15,450 | $7.15 | $110.5K | 19,099+423% |
| Sep 17, 2024 | Lu Hongbo | Director | Buy | 476,190 | $10.50 | $5.00M0.5% OS | 476,190 |
| Sep 12, 2024 | Vignola Mark J. | Chief Financial Officer | Sell | 10,000 | $11.00 | $110.0K | 91,940 |
| Sep 11, 2024 | Quigley Jill M. | Sell | 17,235 | $10.00 | $172.3K | 15,000-53% | |
| Aug 5, 2024 | Quigley Jill M. | Sell | 15,000 | $7.57 | $113.6K | 23,857-39% | |
| Jul 17, 2024 | GORDON CARL L | Director | Sell | 56,164 | $10.00 | $561.6K | 4,843,421 |
| Jul 17, 2024 | Quigley Jill M. | Sell | 14,765 | $10.00 | $147.7K | 30,000-33% | |
| Jun 4, 2024 | Yoon Seokho Bryan | COO and General Counsel | Buy | 4,791 | $4.44 | $21.3K | 91,940 |
| Apr 3, 2024 | Vivo Opportunity, LLC | 10% Owner | Sell | 420,663 | $6.65 | $2.80M | 4,203,957 |
| Dec 4, 2023 | Yoon Seokho Bryan | COO and General Counsel | Buy | 743 | $3.78 | $2.8K | 18,399 |
| Jun 2, 2023 | Sundaram Senthil Vel | Chief Executive Officer | Buy | 2,111 | $1.41 | $3.0K | 9,770+28% |
| Jun 2, 2023 | Vignola Mark J. | Chief Financial Officer | Buy | 9,997 | $1.41 | $14.1K | 17,656+131% |
| Feb 3, 2023 | Yoon Seokho Bryan | COO and General Counsel | Buy | 3 | $1.41 | $4.23 | 7,659 |
| Dec 28, 2022 | ORBIMED ADVISORS LLC | Director | Buy | 137,931 | $7.25 | $1.00M | 4,882,854 |
| Dec 23, 2022 | Vivo Opportunity, LLC | 10% Owner | Buy | 758,620 | $7.25 | $5.50M0.8% OS | 4,340,212 |
| Nov 28, 2022 | LAV Biosciences Fund V, L.P. | 10% Owner | Sell | 1,500,000 | $5.50 | $8.25M1.7% OS | 1,059,523-59% |
| Sep 8, 2022 | Vivo Opportunity, LLC | 10% Owner | Buy | 600,000 | $3.60 | $2.16M0.7% OS | 3,581,592 |
| Aug 18, 2022 | ORBIMED ADVISORS LLC | Director | Buy | 3,690,000 | $2.42 | $8.93M4.1% OS | 4,744,923+350% |
| Aug 16, 2022 | Vivo Opportunity, LLC | 10% Owner | Buy | 2,624,239 | $2.66 | $6.98M2.9% OS | 2,981,592+734% |
| Jun 8, 2022 | Yoon Seokho Bryan | COO and General Counsel | Buy | 7,656 | $1.47 | $11.3K | 7,656 |
TERN Insider Buying Activity
The following table shows recent insider purchases of Terns Pharmaceuticals, Inc. (TERN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | Gengos Andrew | Chief Financial Officer | Buy | 10,000 | $3.93 | $39.3K | 25,000+67% |
| Jun 25, 2025 | Burroughs Amy L. | Chief Executive Officer | Buy | 23,314 | $3.87 | $90.2K | 47,083+98% |
| Jun 16, 2025 | Gengos Andrew | Chief Financial Officer | Buy | 15,000 | $3.81 | $57.1K | 15,000 |
| Feb 3, 2025 | Burroughs Amy L. | Chief Executive Officer | Buy | 510 | $5.11 | $2.6K | 19,609 |
| Feb 3, 2025 | Jung Melita Sun | Chief Business Officer | Buy | 2,250 | $5.11 | $11.5K | 2,250 |
| Dec 9, 2024 | Burroughs Amy L. | Chief Executive Officer | Buy | 15,450 | $7.15 | $110.5K | 19,099+423% |
| Sep 17, 2024 | Lu Hongbo | Director | Buy | 476,190 | $10.50 | $5.00M0.5% OS | 476,190 |
| Jun 4, 2024 | Yoon Seokho Bryan | COO and General Counsel | Buy | 4,791 | $4.44 | $21.3K | 91,940 |
| Dec 4, 2023 | Yoon Seokho Bryan | COO and General Counsel | Buy | 743 | $3.78 | $2.8K | 18,399 |
| Jun 2, 2023 | Sundaram Senthil Vel | Chief Executive Officer | Buy | 2,111 | $1.41 | $3.0K | 9,770+28% |
| Jun 2, 2023 | Vignola Mark J. | Chief Financial Officer | Buy | 9,997 | $1.41 | $14.1K | 17,656+131% |
| Feb 3, 2023 | Yoon Seokho Bryan | COO and General Counsel | Buy | 3 | $1.41 | $4.23 | 7,659 |
| Dec 28, 2022 | ORBIMED ADVISORS LLC | Director | Buy | 137,931 | $7.25 | $1.00M | 4,882,854 |
| Dec 23, 2022 | Vivo Opportunity, LLC | 10% Owner | Buy | 758,620 | $7.25 | $5.50M0.8% OS | 4,340,212 |
| Sep 8, 2022 | Vivo Opportunity, LLC | 10% Owner | Buy | 600,000 | $3.60 | $2.16M0.7% OS | 3,581,592 |
| Aug 18, 2022 | ORBIMED ADVISORS LLC | Director | Buy | 3,690,000 | $2.42 | $8.93M4.1% OS | 4,744,923+350% |
| Aug 16, 2022 | Vivo Opportunity, LLC | 10% Owner | Buy | 2,624,239 | $2.66 | $6.98M2.9% OS | 2,981,592+734% |
| Jun 8, 2022 | Yoon Seokho Bryan | COO and General Counsel | Buy | 7,656 | $1.47 | $11.3K | 7,656 |
TERN Insider Selling Activity
The following table shows recent insider sales of Terns Pharmaceuticals, Inc. (TERN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | Burroughs Amy L. | director, officer: Chief Executive Officer | Sell | 14,583 | $46.71 | $681.1K | 291,746 |
| Feb 18, 2026 | Burroughs Amy L. | director, officer: Chief Executive Officer | Sell | 14,583 | $39.19 | $571.6K | 301,218 |
| Feb 17, 2026 | Burroughs Amy L. | Chief Executive Officer | Sell | 14,583 | $39.19 | $571.6K | 0 |
| Jan 16, 2026 | Burroughs Amy L. | director, officer: Chief Executive Officer | Sell | 68,749 | $37.07 | $2.55M | 296,497 |
| Jan 6, 2026 | Burroughs Amy L. | director, officer: Chief Executive Officer | Sell | 71,339 | $38.10 | $2.72M | 138,976-34% |
| Jan 6, 2026 | Kuriakose Emil | officer: Chief Medical Officer | Sell | 1,155 | $38.57 | $44.6K | 51,320 |
| Nov 5, 2025 | Quigley Jill M. | Sell | 24,520 | $18.00 | $441.4K | 0Exit | |
| Oct 2, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 944 | $7.85 | $7.4K | 51,520 |
| Jul 3, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 853 | $4.27 | $3.6K | 52,464 |
| Apr 2, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 952 | $2.49 | $2.4K | 53,317 |
| Jan 6, 2025 | Kuriakose Emil | Chief Medical Officer | Sell | 4,481 | $5.71 | $25.6K | 54,269 |
| Jan 6, 2025 | Quigley Jill M. | Sell | 15,000 | $5.76 | $86.5K | 8,760-63% | |
| Jan 6, 2025 | Vignola Mark J. | Chief Financial Officer | Sell | 17,188 | $5.76 | $99.0K | 83,811 |
| Sep 12, 2024 | Vignola Mark J. | Chief Financial Officer | Sell | 10,000 | $11.00 | $110.0K | 91,940 |
| Sep 11, 2024 | Quigley Jill M. | Sell | 17,235 | $10.00 | $172.3K | 15,000-53% | |
| Aug 5, 2024 | Quigley Jill M. | Sell | 15,000 | $7.57 | $113.6K | 23,857-39% | |
| Jul 17, 2024 | GORDON CARL L | Director | Sell | 56,164 | $10.00 | $561.6K | 4,843,421 |
| Jul 17, 2024 | Quigley Jill M. | Sell | 14,765 | $10.00 | $147.7K | 30,000-33% | |
| Apr 3, 2024 | Vivo Opportunity, LLC | 10% Owner | Sell | 420,663 | $6.65 | $2.80M | 4,203,957 |
| Nov 28, 2022 | LAV Biosciences Fund V, L.P. | 10% Owner | Sell | 1,500,000 | $5.50 | $8.25M1.7% OS | 1,059,523-59% |
TERN Insiders
Burroughs Amy L.
director, officer: Chief Executive Officer
Bought $203.3KSold $7.09M
8 tradesLast: Mar 17, 2026
Similar Stocks to TERN
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B